Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Vagal afferent cholecystokinin receptor activation is required for glucagon-like peptide-1-induced satiation

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Differences in gastrointestinal hormones and appetite ratings among obesity classes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gastric Aspiration Improves Postprandial Glucose Tolerance Without Causing a Compensatory Increase in Appetite and Food Intake

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Jan Fahrenkrug (6/6 1947 - 10/11 2021)

    Research output: Contribution to journalEditorialResearchpeer-review

  4. Entero-pancreatic hormone secretion, gastric emptying, and glucose absorption after frequently sampled meal tests

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Cholecystokinin and panic disorder: reflections on the history and some unsolved questions

    Research output: Contribution to journalReviewResearchpeer-review

  • Vasiliki Vana
  • Michelle K Laerke
  • Jens F Rehfeld
  • Myrtha Arnold
  • Oksana Dmytriyeva
  • Wolfgang Langhans
  • Thue W Schwartz
  • Harald S Hansen
View graph of relations

Peripheral glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK) are secreted from enteroendocrine cells, and their plasma concentrations increase in response to eating. While the satiating effect of gut-derived CCK on food-intake control is well documented, the effect of peripheral GLP-1 is less clear. There is evidence that native GLP-1 can inhibit food intake only in the fed state but not in the fasting state. We therefore hypothesized that other gut peptides released during a meal might influence the subsequent effect of endogenous GLP-1 and investigated whether CCK could do so. We found that intraperitoneal injection of CCK in food-restricted mice inhibited food intake during the first 30-minute segment of a 1-hour session of ad libitum chow intake and that mice compensated by increasing their intake during the second half of the session. Importantly, this compensatory behaviour was abolished by an intraperitoneal injection of GLP-1 administered following an intraperitoneal injection of CCK and prior to the 1-hour session. In vivo activation of the free fatty acid 1 (FFA1) receptor with orally administered TAK875 increased plasma CCK concentration and, consistent with the effect of exogenous CCK, we found that prior oral administration of TAK875 increased the eating inhibitory effect of peripherally administered GLP-1. To examine the role of the vagus nerve in this effect, we utilized a saporin-based lesioning procedure to selectively ablate the CCK receptor-expressing gastrointestinal vagal afferent neurones (VANs). We found that the combined anorectic effect of TAK875 and GLP-1 was significantly attenuated in the absence of CCK receptor expressing VANs. Taken together, our results indicate that endogenous CCK interacts with GLP-1 to promote satiation and that activation of the FFA1 receptor can initiate this interaction by stimulating the release of CCK.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Issue number2
Pages (from-to)268-280
Number of pages13
Publication statusPublished - Feb 2022

Bibliographical note

© 2021 John Wiley & Sons Ltd.

ID: 72964952